Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative

Shumin Zhang, Lajos Gera, Kenza Mamouni, Xin Li, Zhengjia Chen, Omer Kucuk, Daqing Wu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality. Despite some success in transiently controlling clinical symptoms with docetaxel-based therapy, PCa patients become docetaxel-resistant and inevitably progress with no cure. We synthesized an acyl-tyrosine bisphosphonate amide derivative, BKM1644, with the intent of targeting bone metastatic PCa and enhancing docetaxel's efficacy. BKM1644 exhibits potent anti-cancer activity in the NCI-60 panel and effectively inhibits the proliferation of metastatic, castration-resistant PCa (mCRPC) cells, with IC50 ranging between 2.1 μM and 6.3 μM. Significantly, BKM1644 sensitizes mCRPC cells to docetaxel treatment. Mice with pre-established C4-2 tumors in the tibia show a marked decrease in serum prostate-specific antigen (control: 173.72 ± 37.52 ng/ml, combined treatment: 64.45 ± 22.19 ng/ml; p < 0.0001) and much improved bone architecture after treatment with the combined regimen. Mechanistic studies found that docetaxel temporarily but significantly increases survivin, an anti-apoptotic protein whose overexpression has been correlated with PCa bone metastasis and therapeutic resistance. Intriguingly, BKM1644 effectively inhibits survivin expression, which may antagonize docetaxel-induced survivin in bone metastatic PCa cells. Signal transducer and activator of transcription 3 (Stat3) may be involved in the suppression of survivin transcription by BKM1644, as confirmed by a survivin reporter assay. Collectively, these data indicate that BKM1644 could be a promising small-molecule agent to improve docetaxel efficacy and retard the bone metastatic growth of PCa.

Original languageEnglish (US)
Pages (from-to)27489-27498
Number of pages10
JournalOncotarget
Volume7
Issue number19
DOIs
StatePublished - May 10 2016

Fingerprint

docetaxel
Prostatic Neoplasms
Growth
Bone and Bones
Castration
Neoplasm Metastasis
Therapeutics
STAT3 Transcription Factor
Bone Neoplasms
Apoptosis Regulatory Proteins
Bone Development
Diphosphonates
Prostate-Specific Antigen
Tibia
Inhibitory Concentration 50
Neoplasms

Keywords

  • Bone metastasis
  • Docetaxel resistance
  • Preclinical models
  • Prostate cancer
  • Survivin inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative. / Zhang, Shumin; Gera, Lajos; Mamouni, Kenza; Li, Xin; Chen, Zhengjia; Kucuk, Omer; Wu, Daqing.

In: Oncotarget, Vol. 7, No. 19, 10.05.2016, p. 27489-27498.

Research output: Contribution to journalArticle

Zhang, Shumin ; Gera, Lajos ; Mamouni, Kenza ; Li, Xin ; Chen, Zhengjia ; Kucuk, Omer ; Wu, Daqing. / Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative. In: Oncotarget. 2016 ; Vol. 7, No. 19. pp. 27489-27498.
@article{df713a5d8f1f4a838d88ba3c11b88fdf,
title = "Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative",
abstract = "Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality. Despite some success in transiently controlling clinical symptoms with docetaxel-based therapy, PCa patients become docetaxel-resistant and inevitably progress with no cure. We synthesized an acyl-tyrosine bisphosphonate amide derivative, BKM1644, with the intent of targeting bone metastatic PCa and enhancing docetaxel's efficacy. BKM1644 exhibits potent anti-cancer activity in the NCI-60 panel and effectively inhibits the proliferation of metastatic, castration-resistant PCa (mCRPC) cells, with IC50 ranging between 2.1 μM and 6.3 μM. Significantly, BKM1644 sensitizes mCRPC cells to docetaxel treatment. Mice with pre-established C4-2 tumors in the tibia show a marked decrease in serum prostate-specific antigen (control: 173.72 ± 37.52 ng/ml, combined treatment: 64.45 ± 22.19 ng/ml; p < 0.0001) and much improved bone architecture after treatment with the combined regimen. Mechanistic studies found that docetaxel temporarily but significantly increases survivin, an anti-apoptotic protein whose overexpression has been correlated with PCa bone metastasis and therapeutic resistance. Intriguingly, BKM1644 effectively inhibits survivin expression, which may antagonize docetaxel-induced survivin in bone metastatic PCa cells. Signal transducer and activator of transcription 3 (Stat3) may be involved in the suppression of survivin transcription by BKM1644, as confirmed by a survivin reporter assay. Collectively, these data indicate that BKM1644 could be a promising small-molecule agent to improve docetaxel efficacy and retard the bone metastatic growth of PCa.",
keywords = "Bone metastasis, Docetaxel resistance, Preclinical models, Prostate cancer, Survivin inhibitor",
author = "Shumin Zhang and Lajos Gera and Kenza Mamouni and Xin Li and Zhengjia Chen and Omer Kucuk and Daqing Wu",
year = "2016",
month = "5",
day = "10",
doi = "10.18632/oncotarget.8481",
language = "English (US)",
volume = "7",
pages = "27489--27498",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative

AU - Zhang, Shumin

AU - Gera, Lajos

AU - Mamouni, Kenza

AU - Li, Xin

AU - Chen, Zhengjia

AU - Kucuk, Omer

AU - Wu, Daqing

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality. Despite some success in transiently controlling clinical symptoms with docetaxel-based therapy, PCa patients become docetaxel-resistant and inevitably progress with no cure. We synthesized an acyl-tyrosine bisphosphonate amide derivative, BKM1644, with the intent of targeting bone metastatic PCa and enhancing docetaxel's efficacy. BKM1644 exhibits potent anti-cancer activity in the NCI-60 panel and effectively inhibits the proliferation of metastatic, castration-resistant PCa (mCRPC) cells, with IC50 ranging between 2.1 μM and 6.3 μM. Significantly, BKM1644 sensitizes mCRPC cells to docetaxel treatment. Mice with pre-established C4-2 tumors in the tibia show a marked decrease in serum prostate-specific antigen (control: 173.72 ± 37.52 ng/ml, combined treatment: 64.45 ± 22.19 ng/ml; p < 0.0001) and much improved bone architecture after treatment with the combined regimen. Mechanistic studies found that docetaxel temporarily but significantly increases survivin, an anti-apoptotic protein whose overexpression has been correlated with PCa bone metastasis and therapeutic resistance. Intriguingly, BKM1644 effectively inhibits survivin expression, which may antagonize docetaxel-induced survivin in bone metastatic PCa cells. Signal transducer and activator of transcription 3 (Stat3) may be involved in the suppression of survivin transcription by BKM1644, as confirmed by a survivin reporter assay. Collectively, these data indicate that BKM1644 could be a promising small-molecule agent to improve docetaxel efficacy and retard the bone metastatic growth of PCa.

AB - Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality. Despite some success in transiently controlling clinical symptoms with docetaxel-based therapy, PCa patients become docetaxel-resistant and inevitably progress with no cure. We synthesized an acyl-tyrosine bisphosphonate amide derivative, BKM1644, with the intent of targeting bone metastatic PCa and enhancing docetaxel's efficacy. BKM1644 exhibits potent anti-cancer activity in the NCI-60 panel and effectively inhibits the proliferation of metastatic, castration-resistant PCa (mCRPC) cells, with IC50 ranging between 2.1 μM and 6.3 μM. Significantly, BKM1644 sensitizes mCRPC cells to docetaxel treatment. Mice with pre-established C4-2 tumors in the tibia show a marked decrease in serum prostate-specific antigen (control: 173.72 ± 37.52 ng/ml, combined treatment: 64.45 ± 22.19 ng/ml; p < 0.0001) and much improved bone architecture after treatment with the combined regimen. Mechanistic studies found that docetaxel temporarily but significantly increases survivin, an anti-apoptotic protein whose overexpression has been correlated with PCa bone metastasis and therapeutic resistance. Intriguingly, BKM1644 effectively inhibits survivin expression, which may antagonize docetaxel-induced survivin in bone metastatic PCa cells. Signal transducer and activator of transcription 3 (Stat3) may be involved in the suppression of survivin transcription by BKM1644, as confirmed by a survivin reporter assay. Collectively, these data indicate that BKM1644 could be a promising small-molecule agent to improve docetaxel efficacy and retard the bone metastatic growth of PCa.

KW - Bone metastasis

KW - Docetaxel resistance

KW - Preclinical models

KW - Prostate cancer

KW - Survivin inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84968913715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968913715&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8481

DO - 10.18632/oncotarget.8481

M3 - Article

C2 - 27050371

AN - SCOPUS:84968913715

VL - 7

SP - 27489

EP - 27498

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -